Health CareMedical Equipment and Services
  • Price (GBX)1,152.00
  • Today's Change-25.50 / -2.17%
  • Shares traded4.33m
  • 1 Year change-6.15%
  • Beta0.6466
Data delayed at least 20 minutes, as of Mar 23 2023 17:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. It is focused on the repair, regeneration and replacement of soft and hard tissue. The Company operates through three segments: Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that helps surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.27bn
  • Net income in GBP182.58m
  • Incorporated1937
  • Employees19.01k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Ypsomed Holding AG432.21m27.91m2.21bn2.00k75.104.9023.745.122.432.4337.6137.290.63795.416.20252,988.604.124.976.407.5526.0927.306.467.000.45710.380.249324.1815.163.60297.61-12.9627.27-14.33
Elekta AB (publ)1.26bn64.28m2.31bn4.61k37.253.1515.491.832.132.1341.8325.190.57553.292.673,364,344.002.954.845.358.8637.4741.035.128.880.78153.530.369455.055.706.33-7.9755.9812.7119.14
GN Store Nord A/S2.22bn60.74m2.34bn7.89k35.932.699.341.053.993.99145.9953.140.69033.435.102,368,
Ambu A/S540.21m11.29m2.69bn4.41k265.196.2456.244.970.38160.381618.0316.220.68181.866.631,030,846.001.435.081.686.2756.8160.
Getinge AB2.24bn196.95m4.59bn11.11k24.952.0713.462.059.159.15103.87110.280.58582.715.68--5.213.976.545.1847.4047.998.906.561.5725.030.160539.884.604.69-16.1317.85-7.3423.16
ConvaTec Group PLC1.70bn51.50m4.68bn10.03k90.583.5521.022.760.02530.02530.83170.64480.57053.006.03--1.732.662.043.0353.2654.
Amplifon SpA1.88bn158.02m5.95bn13.20k37.666.4216.073.170.78860.78869.344.620.597723.0711.42160,600.705.044.476.955.9424.4256.618.447.410.48918.830.592331.928.7810.8511.0711.939.8921.40
Demant A/S2.34bn270.28m6.11bn20.57k22.205.82--2.6110.069.2187.1938.360.72031.915.51957,948.408.328.6014.1514.2374.4474.8711.5511.630.615319.620.63780.0010.058.36-15.655.3315.70--
Smith & Nephew plc4.27bn182.58m10.23bn19.01k56.202.3714.882.400.20850.20854.884.950.49940.76074.26224,578.
Carl Zeiss Meditec AG1.74bn271.71m10.39bn4.22k38.32--66.045.983.423.4221.91--------464,715.90--9.15--11.2058.7057.4715.7112.38--30.61--35.2515.559.8424.3916.9316.0014.87
Koninklijke Philips NV15.78bn-1.43bn12.05bn77.23k--1.02--0.764-1.83-1.8220.2115.030.57832.844.51230,821.00-5.251.64-7.012.2540.3544.47-9.082.620.78274.760.3817--3.910.0528-366.61---1.27--
Sonova Holding AG3.20bn574.01m13.31bn17.07k23.387.4216.964.1510.4810.4858.5533.000.65962.827.71215,544.1012.0310.5016.1913.5571.1171.8018.2417.470.841230.490.456133.6529.297.0214.2012.581.6513.85
Data as of Mar 23 2023. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

26.04%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202042.67m4.89%
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202133.66m3.85%
The Vanguard Group, Inc.as of 01 Mar 202330.95m3.54%
BlackRock Fund Advisorsas of 12 Feb 202124.77m2.84%
Walter Scott & Partners Ltd.as of 01 Mar 202319.31m2.21%
Rathbone Investment Management Ltd.as of 01 Mar 202317.11m1.96%
T. Rowe Price Associates, Inc. (Investment Management)as of 01 Mar 202316.80m1.92%
UBS Asset Management (UK) Ltd.as of 01 Mar 202315.95m1.83%
Legal & General Investment Management Ltd.as of 01 Mar 202315.03m1.72%
Fidelity Management & Research Co. LLCas of 01 Mar 202311.17m1.28%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.